New scanner used for brain tumour patients trialled in world-first
Scientists at the University of Aberdeen and NHS Grampian have been awarded £350,000 of Scottish Government funding to generate never-before-seen images of glioblastoma brain tumours.
The technology is hoped to potentially improve treatment and quality of life for patients, by investigating a new way to scan glioblastoma brain tumours – the most common and aggressive type, with more than 3000 new patients in the UK diagnosed each year.
Half of all patients die within 15 months of diagnosis even after extensive surgery, radiotherapy and chemotherapy.
READ MORE: Anas Sarwar urged to whip Scottish Labour MPs against welfare cuts
Field cycling imaging (FCI) is a new and specialist type of low-field MRI scan pioneered in Aberdeen and has already been found to be effective in detecting tumours in breast tissue and brain damage in stroke patients.
It is hoped it can now be used to help brain tumour patients.
MRI scanners were invented at the University of Aberdeen 50 years ago, but the new FCI scanner is the only one of its type used on patients anywhere in the world.
The FCI derives from MRI but can work at low and ultra-low magnetic fields which means it is capable of seeing how organs are affected by diseases in ways that were previously not possible, and can vary the strength of the magnetic field during the patient's scan – acting like multiple scanners and extracting more information about the tissues.
The new technology can detect tumours without having to inject dye into the body, which can be associated with kidney damage and allergic reactions in some patients.
The team of doctors and scientists involved will scan glioblastoma patients undergoing chemotherapy after surgery and chemoradiotherapy.
It is hoped the research will establish that, unlike conventional MRI scans, FCI can tell the difference between tumour growth and progression, and 'pseudo-progression' which looks like tumour but is not cancerous tissue, which could improve care and quality of life.
(Image: PA)
Professor Anne Kiltie, Friends of ANCHOR chair in clinical oncology at the University of Aberdeen, who is leading the study said: 'We already have evidence that FCI is effective in detecting tumours in breast tissue and brain damage in patients following a stroke.
'Applying this exciting new technology to glioblastoma patients could give us a much more accurate and detailed picture of what is going on in their brain.
'If we can detect true tumour progression early, we can swap the patient to a potentially more beneficial type of chemotherapy.
'Also, being able to verify that a patient has pseudo-progression will prevent effective chemotherapy being stopped too early, because it was thought that the tumour has progressed, thus worsening prognosis.
'Providing certainty will also reduce anxiety for both patients and relatives and improve the quality of life of patients.
'Importantly, having a reliable method to identify progressive disease will allow development and more precise evaluation of emerging potential treatments. This is of particular importance as patients currently have a limited choice of treatments for combating their cancer.
'Ultimately, this study and related future work will improve quality, effectiveness and healthcare cost-effectiveness in the treatment of glioblastoma patients across Scotland and beyond.'
Sarah-Jane Hogg, chief executive at Friends of ANCHOR, added: 'This is a really promising development and another example of the pioneering work coming out of the University of Aberdeen.
'Professor Kiltie's role at the University is fully funded by Friends of ANCHOR through our Dream Big appeal, and our thanks go to our donors and fundraisers for the part they've played in supporting this work.'
A spokesperson for The Brain Tumour Charity said: 'This pioneering technology is a promising step forward for people who have been diagnosed with the most aggressive type of brain tumour.
'It's positive news in contrast to the accounts we often hear about delays to diagnosis, limited treatment options, and the struggle to get vital innovations to the NHS front line.
'We welcome this, and The Brain Tumour Charity will continue working with clinicians and policymakers in Scotland – and the rest of the UK – to help bring advances to patients more quickly.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Glasgow Times
44 minutes ago
- Glasgow Times
Chris Hoy calls for systemic change in testing for prostate cancer
The 49-year old cyclist was diagnosed with stage four prostate cancer in 2023 and was told last year that it has spread to his bones and is terminal. NHS guidance says men over the age of 50 are at highest risk of developing prostate cancer, but Sir Chris wants to help men get screened earlier. He said: 'I was diagnosed with stage four prostate cancer at 47. By this age, my prostate cancer was advanced and could have been progressing from when I was 45 or even younger. 'With prostate cancer, the earlier you find it, the easier it is to treat. We need the system to change to enable more men to get diagnosed earlier, and stop them getting the news I got.' One option is a PSA blood test which checks the level of prostate-specific antigens in the blood, A high reading may be a sign of a prostate condition. NHS guidance says these tests are not routinely used as they are not reliable, but men over 50 can ask GPs for one. Sir Chris's comments came after Prostate Cancer UK urged the UK Government for an overhaul of NHS guidelines to encourage GPs to proactively speak to men at high risk from 45 years old. #ProstateCancer has become the most common cancer in England. However, for a disease that affects 1 in 8 men, there's still no screening programme and outdated NHS guidelines prevent lifesaving conversations with men at highest risk. ➡️ Read more: — Prostate Cancer UK (@ProstateUK) January 28, 2025 According to the charity, around one in eight men in the UK will get prostate cancer, which occurs when cells in the prostate start to grow in an uncontrolled way and, if not detected early, risks spreading. Sir Chris added: 'I believe men at highest risk, for example men with a family history like me or black men, should be contacted by their GP earlier on to discuss a simple PSA blood test that can check for signs of prostate cancer. Then if there are any issues, they can get it treated it at an earlier stage. 'I've told my story to help raise awareness about the most common cancer in men and get more thinking about their risk and what they can do, but it shouldn't all be men's responsibility. 'I've faced many challenges in my life, and going public with my prostate cancer diagnosis was certainly one of them. 'I've been incredibly lucky to have so much support from my family, friends and the general public. The kindness has lifted me up and given me a sense of purpose, and I'm committed to taking that forward and using my platform to raise awareness of the most common cancer in men and help more men at risk to come forward and get tested.' The Scottish cyclist has launched his own charity cycling challenge, Tour de 4, with the aim of changing perceptions around stage four cancer. The challenge will take place on September 7 in Glasgow with a final registration phase open for riders to sign up. Speaking about Sir Chris, Laura Kerby, chief executive at Prostate Cancer UK, said: 'His bravery and tireless work to raise awareness has already made a huge impact. 'In just a few months after Sir Chris went public with his diagnosis last year, over 286,000 people used our online risk checker to learn more about the disease, find out their own risk and learn what they can choose to do about it. 'His bravery has inspired so many men to take action, and he has undoubtedly saved lives. 'One in eight men will get prostate cancer. The earlier it's found, the easier it is to treat — but there's currently no screening programme in the UK. So if, like Sir Chris, you have a family history of the disease, or if you're black, we strongly encourage you to speak to your GP about testing from the age of 45. 'We don't think it's right that the responsibility is all on men's shoulders, so we're calling on the Health Secretary to overhaul outdated NHS guidelines so that GPs are empowered to actually start conversations with these men at highest risk.' The Department for Health and Social Care has been contacted for comment.
Glasgow Times
44 minutes ago
- Glasgow Times
ADHD waiting list led to rise in unregulated private providers
The ADHD taskforce, commissioned by NHS England with the support of the Government, has published an interim report saying the system for diagnosing and managing ADHD needs to be overhauled. At the moment, ADHD assessment and treatment in England is provided by highly specialised doctors in secondary care. But the report warned: 'Inability to access NHS services has led to a significant growth in the use of private providers that are not regulated, resulting in two-tier access to services, diagnosis and treatment; one for those who can pay and another for those who cannot. 'This drives health inequalities and links to disproportionate impacts and outcomes in the education and justice systems, employment and health.' Experts behind the study said waiting times for NHS ADHD services 'have escalated and are unacceptably long' and demand on services is 'very likely' to continue to rise. The taskforce concluded that ADHD is not solely the remit of the NHS and other health providers, with schools being vital for identifying and meeting needs at an early stage. And while a clinical diagnosis of ADHD via the NHS is required if a person needs medication, early support can still be provided to others. The report said: 'We need timely recognition and early support of suspected ADHD and neurodivergence across all settings. 'This is especially important in schools and the early years, to prevent adverse impacts and costly outcomes in the future. This should be needs-led and not require a clinical diagnosis.' The report also suggested there is no evidence of over-diagnosis of ADHD in the UK. It argued: 'England and the rest of the UK have much lower service recognition and treatment rates of ADHD diagnosis compared with other European countries. 'Recent data show a very high level of under-recognition and under-treatment of strictly diagnosed ADHD, with significant inequalities in access to care.' The report also addressed concerns about potential 'over-medicalisation and over-diagnosis', including worries that people are self-diagnosing ADHD based on information from social media. However, the report, said that 'currently there is no good evidence on what percentage of those waiting to see a clinician have self-diagnosed ADHD using social media and eventually meet or do not meet ADHD diagnostic criteria after a high-quality assessment. 'We only know currently that in England, recognised rates of ADHD are lower than the expected prevalence of ADHD.' Currently, the estimated economic costs of not treating ADHD are around £17 billion to the UK economy, the report went on. This includes through lower tax contributions, people needing state benefits and more likely to be not in education, employment or training, or who are long-term unemployed. 'Many of these costs are avoidable, as with appropriate, early support, people with ADHD can thrive,' it said. Professor Anita Thapar, chair of the ADHD Taskforce, said: 'The recommendations put forward by the taskforce will require action across Government and cross-sector organisations to make the necessary changes to improve the lives of people with ADHD. 'We need to get this right, to make sure people get early diagnosis and support, not just in the NHS but across society.' Dr Adrian James, NHS England's medical director for mental health and neurodiversity, said: 'We know that too many people with ADHD have been waiting for too long for support, which is why we launched the taskforce last year to help respond to the significant growth in the need for care. 'It is clear that much more needs to be done to improve ADHD assessment and care in England and ensure people can get a timely diagnosis, and we welcome the findings from the interim report, and look forward to its final conclusions later this year.' The NHS has launched publicly-available data collection on ADHD referrals and waiting times to help local teams better understand how they are performing. By March 2026, the Government also aims for six in 10 pupils to have access to a mental health support team in school.
The Independent
an hour ago
- The Independent
Desperate patients using unregulated ADHD services due to long NHS waiting lists
A taskforce has claimed that long NHS waiting lists for ADHD diagnosis and support have caused a 'significant growth in the use of private providers that are not regulated'. The ADHD taskforce has published an interim report saying the system for diagnosing and managing ADHD needs to be overhauled. The taskforce was commissioned by NHS England with the support of the Government. At the moment, ADHD assessment and treatment in England is provided by highly specialised doctors in secondary care. But the report warned: 'Inability to access NHS services has led to a significant growth in the use of private providers that are not regulated, resulting in two-tier access to services, diagnosis and treatment; one for those who can pay and another for those who cannot. 'This drives health inequalities and links to disproportionate impacts and outcomes in the education and justice systems, employment and health.' Experts behind the study said waiting times for NHS ADHD services 'have escalated and are unacceptably long' and demand on services is 'very likely' to continue to rise. The taskforce concluded that ADHD is not solely the remit of the NHS and other health providers, with schools being vital for identifying and meeting needs at an early stage. And while a clinical diagnosis of ADHD via the NHS is required if a person needs medication, early support can still be provided to others. The report said: 'We need timely recognition and early support of suspected ADHD and neurodivergence across all settings. 'This is especially important in schools and the early years, to prevent adverse impacts and costly outcomes in the future. This should be needs-led and not require a clinical diagnosis.' The report also suggested there is no evidence of over-diagnosis of ADHD in the UK. It argued: 'England and the rest of the UK have much lower service recognition and treatment rates of ADHD diagnosis compared with other European countries. 'Recent data show a very high level of under-recognition and under-treatment of strictly diagnosed ADHD, with significant inequalities in access to care.' The report also addressed concerns about potential 'over-medicalisation and over-diagnosis', including worries that people are self-diagnosing ADHD based on information from social media. However, the report, said that 'currently there is no good evidence on what percentage of those waiting to see a clinician have self-diagnosed ADHD using social media and eventually meet or do not meet ADHD diagnostic criteria after a high-quality assessment. 'We only know currently that in England, recognised rates of ADHD are lower than the expected prevalence of ADHD.' Currently, the estimated economic costs of not treating ADHD are around £17 billion to the UK economy, the report went on. This includes through lower tax contributions, people needing state benefits and more likely to be not in education, employment or training, or who are long-term unemployed. 'Many of these costs are avoidable, as with appropriate, early support, people with ADHD can thrive,' it said. Professor Anita Thapar, chair of the ADHD Taskforce, said: 'The recommendations put forward by the taskforce will require action across Government and cross-sector organisations to make the necessary changes to improve the lives of people with ADHD. 'We need to get this right, to make sure people get early diagnosis and support, not just in the NHS but across society.' Dr Adrian James, NHS England's medical director for mental health and neurodiversity, said: 'We know that too many people with ADHD have been waiting for too long for support, which is why we launched the taskforce last year to help respond to the significant growth in the need for care. 'It is clear that much more needs to be done to improve ADHD assessment and care in England and ensure people can get a timely diagnosis, and we welcome the findings from the interim report, and look forward to its final conclusions later this year.' The NHS has launched publicly-available data collection on ADHD referrals and waiting times to help local teams better understand how they are performing. By March 2026, the Government also aims for six in 10 pupils to have access to a mental health support team in school.
